Clinical Trial Update: APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating APX005M in combination with concurrent chemoradiation for resectable esophageal and gastroesophageal junction cancers has completed enr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastroesophageal Cancer

Drugs mentioned

• APX005M

Snippet

Sponsor: Apexigen America, Inc. | Conditions: Esophageal Cancer, GastroEsophageal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-05-02